# ENTA catalysts: ENANTA PHARMACEUTICALS INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/enta/catalysts

> ENANTA PHARMACEUTICALS INC (ENTA) has 4 upcoming catalysts. The next is the zelicapavir primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ENANTA PHARMACEUTICALS INC |
| Ticker | ENTA (Nasdaq) |
| SEC CIK | 1177648 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/enta |

## Cash runway

Cash $211.5M as of 2026-06-30; quarterly burn $10.0M; about 63.6 months of runway at that rate (XBRL company facts, accession 0001193125-26-345719).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2024 | [EDP-323 topline data readout](https://sec-api.dev/pdufa/edp-323) | ENTA |  | completed, positive | "In September 2024, Enanta announced positive topline results for EDP-323 in a Phase 2a challenge study of healthy adults infected with RSV." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000095017024130553/enta-ex99_1.htm)) |
| November 25, 2024 | [ENANTA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/enta/catalysts) | ENTA |  | completed | "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000095017024130553/enta-ex99_1.htm)) |
| December 9, 2024 | [Zelicapavir topline data readout](https://sec-api.dev/pdufa/zelicapavir) | ENTA |  | completed, positive | "As noted in Item 7.01 above, Enanta announced positive topline data from its Phase 2 pediatric study of zelicapavir for the treatment of RSV on December 9, 2024." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1177648/000119312524272936/d706648d8k.htm)) |
| February 10, 2025 | [ENANTA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/enta/catalysts) | ENTA |  | completed | "Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000095017025017035/enta-ex99_1.htm)) |
| May 12, 2025 | [ENANTA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/enta/catalysts) | ENTA |  | completed | "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000095017025069155/enta-ex99_1.htm)) |
| June 23, 2025 | [EDP-938 primary completion](https://sec-api.dev/pdufa/edp-938) | ENTA | RSV Infection | completed | "NCT05568706 (A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-23 (ACTUAL); Lead Sponsor Enanta Pharmaceuticals, Inc; Results First Posted 2026-08-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05568706)) |
| Q3 2025 | [Zelicapavir topline data readout](https://sec-api.dev/pdufa/zelicapavir) | ENTA |  | scheduled | "Met Target Enrollment for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV); On Track to Report Topline Data in Late 3Q 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000095017025069155/enta-ex99_1.htm)) |
| August 11, 2025 | [ENANTA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/enta/catalysts) | ENTA |  | completed | "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312525177941/enta-ex99_1.htm)) |
| September 29, 2025 | [Zelicapavir topline data readout](https://sec-api.dev/pdufa/zelicapavir) | ENTA |  | completed, positive | "As noted in Item 7.01 above, Enanta announced positive topline data from its Phase 2b high-risk adults study of zelicapavir for the treatment of RSV on September 29, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1177648/000119312525221527/d16388d8k.htm)) |
| November 17, 2025 | [ENANTA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/enta/catalysts) | ENTA |  | completed | "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year -Ended September 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312525284633/enta-ex99_1.htm)) |
| February 9, 2026 | [ENANTA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/enta/catalysts) | ENTA |  | completed | "Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312526042812/enta-ex99_1.htm)) |
| May 11, 2026 | [EDP-978 trial start](https://sec-api.dev/pdufa/edp-978) | ENTA |  | completed | "In April, the Company announced the first participant was dosed in a randomized, double-blind, placebo-controlled, first-in-human Phase 1 clinical trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312526216735/enta-ex99_1.htm)) |
| May 11, 2026 | [ENANTA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/enta/catalysts) | ENTA |  | completed | "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312526216735/enta-ex99_1.htm)) |
| August 10, 2026 | [EDP-978 trial start](https://sec-api.dev/pdufa/edp-978) | ENTA |  | completed | "In April, the Company announced that the first participant was dosed in a randomized, double-blind, placebo-controlled, first-in-human Phase 1 clinical trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-ex99_1.htm)) |
| August 10, 2026 | [ENANTA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/enta/catalysts) | ENTA |  | completed | "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-ex99_1.htm)) |
| August 19, 2026 | [EDP-938 topline data readout](https://sec-api.dev/pdufa/edp-938) | ENTA | RSV Infection | completed | "NCT05568706 (A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-23 (ACTUAL); Lead Sponsor Enanta Pharmaceuticals, Inc; Results First Posted 2026-08-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05568706?tab=results)) |
| Q4 2026 | [EDP-978 topline data readout](https://sec-api.dev/pdufa/edp-978) | ENTA |  | scheduled | "The Company is on track to submit an IND in the first quarter, with topline Phase 1 data expected in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312526042812/enta-ex99_1.htm)) |
| Q4 2026 | [Zelicapavir trial start](https://sec-api.dev/pdufa/zelicapavir) | ENTA | RSV, with topline data | scheduled | "On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-ex99_1.htm)) |
| December 2026 | [Zelicapavir primary completion](https://sec-api.dev/pdufa/zelicapavir) | ENTA | RSV Infection; RSV; Respiratory Syncytial Virus (RSV) | scheduled | "NCT07482657 (A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Enanta Pharmaceuticals, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07482657)) |
| Dec 2026 to Mar 2027 | [Zelicapavir topline data readout](https://sec-api.dev/pdufa/zelicapavir) | ENTA | RSV Infection; RSV; Respiratory Syncytial Virus (RSV) | scheduled | "On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-ex99_1.htm)) |
| July 2029 | [Zelicapavir primary completion](https://sec-api.dev/pdufa/zelicapavir) | ENTA | RSV | scheduled | "NCT07908381 (A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Enanta Pharmaceuticals, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07908381)) |
| Jul to Oct 2029 | [Zelicapavir topline data readout](https://sec-api.dev/pdufa/zelicapavir) | ENTA | RSV | scheduled | "NCT07908381 (A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Enanta Pharmaceuticals, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07908381)) |

## Drugs

- [EDP-323](https://sec-api.dev/pdufa/edp-323): 
- [EDP-938](https://sec-api.dev/pdufa/edp-938): RSV Infection
- [EDP-978](https://sec-api.dev/pdufa/edp-978): 
- [Zelicapavir](https://sec-api.dev/pdufa/zelicapavir): rsv, with topline data, rsv in thailand, with topline data, respiratory syncytial virus, RSV Infection, RSV

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/enta/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ENTA catalysts: ENANTA PHARMACEUTICALS INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/enta/catalysts

```bibtex
@misc{secapidev_companies_enta_catalysts_20261116,
  title        = {ENTA catalysts: ENANTA PHARMACEUTICALS INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/enta/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_enta_catalysts_20261116","title":"ENTA catalysts: ENANTA PHARMACEUTICALS INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/enta/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
